Drug
Sapacitabine clinical trials
Also written CYC682.
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 2
Cyclacel Pharmaceuticals, Inc. (7) · Dana-Farber Cancer Institute (1) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Olaparib (1) · Roscovitine (1) · Cyclophosphamide (1) · Rituximab (1) · Decitabine (1) · Venetoclax (1)
Related medicines
As reviewed, each with the page that says it.
- One of Antimetabolites source
Studies
Open first, then newest update. How each study uses sapacitabine is read from its arms, and is right about nine times in ten.
Testing it · 9
- Olaparib + Sapacitabine in BRCA Mutant Breast CancerActive, not recruitingPhase 1Dana-Farber Cancer InstituteNCT03641755Written as Sapacitabine
- Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly PatientsCompletedPhase 2Cyclacel Pharmaceuticals, Inc.NCT00590187Written as Sapacitabine, Arm A
- A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedPhase 3Cyclacel Pharmaceuticals, Inc.NCT01303796Written as Sapacitabine
- A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid TumorsCompletedPhase 1Cyclacel Pharmaceuticals, Inc.NCT00999401Written as sapacitabine and seliciclib
- A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung CancerTerminatedPhase 2Cyclacel Pharmaceuticals, Inc.NCT00885963Written as sapacitabine
- A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell LymphomaTerminatedPhase 2Cyclacel Pharmaceuticals, Inc.NCT00476554Written as Sapacitabine
- Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic SyndromesCompletedPhase 1Cyclacel Pharmaceuticals, Inc.NCT00380653Written as sapacitabine
- Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)TerminatedPhase 2M.D. Anderson Cancer CenterNCT01253460Written as Sapacitabine
- Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)Status unknownPhase 1/2Cyclacel Pharmaceuticals, Inc.NCT01211457Written as sapacitabine and decitabine (Part 1 - completed)
Codes
What other systems call sapacitabine · ClinicalTrials.gg INT004140
- MeSH (NLM) C117959sapacitabineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) W335P73C3LSAPACITABINEConfirmed FDA, NLM, Wikidata
- Wikidata Q7420893sapacitabineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C64541SapacitabineOne source FDA
- DrugBank DB06365One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C117959 | sapacitabine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | W335P73C3L | SAPACITABINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7420893 | sapacitabine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C64541 | Sapacitabine | One source FDA |
| DrugBank | DB06365 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.